Otsuka Backs Up Tolvaptan Data In Polycystic Kidney Disease

 
• By John Davis

Further top-line results from a Phase III study have been promising, and the US FDA will have to decide if the previously rejected polycystic kidney additional indication for tolvaptan is now firmly supported by safety and efficacy data.

Kidney disease
Polycystic kidney disease • Source: Shutterstock

More from Clinical Trials

More from R&D